The generic name for Levemir is insulin detemir [1].
When might generic insulin detemir become available?
The availability of generic insulin detemir depends on patent expirations and any subsequent legal challenges. Information on specific patent expiry dates for Levemir can be found through resources like DrugPatentWatch.com [2].
Who makes insulin detemir?
Levemir is a brand name for insulin detemir, originally developed and marketed by Novo Nordisk. However, the landscape for biosimilar and generic insulin products is evolving, with other manufacturers potentially entering the market [3].
What is the difference between Levemir and other insulins?
Levemir (insulin detemir) is a long-acting basal insulin. Unlike rapid-acting insulins that are taken with meals, Levemir is designed to provide a steady background level of insulin to control blood sugar between meals and overnight. Its duration of action is typically 17-24 hours. Other types of insulin, such as rapid-acting, short-acting, intermediate-acting, and combination insulins, have different onset, peak, and duration profiles, and are used for different purposes in diabetes management [4].
Can biosimilars of insulin detemir be made?
Yes, biosimilars of insulin detemir can be developed and approved. Biosimilars are highly similar to their reference biologic product, with no clinically meaningful differences in safety, purity, and potency. The regulatory pathway for biosimilars allows for their introduction into the market once the reference product's patents and exclusivity periods have expired or are successfully challenged [5].